Melissa Leigh Larson MD
Associate Professor, Internal Medicine, Rush Medical College of Rush Univ
Join to View Full Profile
1725 W Harrison StSte 809Chicago, IL 60612
Phone+1 312-563-2320
Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rush University Medical CenterResidency, Internal Medicine, 2000 - 2003
Rush Medical College of Rush University Medical CenterClass of 2000
Certifications & Licensure
IL State Medical License 2003 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Roles: Contact
Publications & Presentations
PubMed
- Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis.Andrew Palmer, Garth Rauscher, Alexa Schoen, Madelyn Burkart, Ashley Dunton
Blood Cancer Journal. 2025-10-06 - 3 citationsAir pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia.Andrew Palmer, Garth Rauscher, Ivy Abraham, Madelyn Burkart, Ami Dave
Blood Advances. 2024-09-10 - COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US population.Stephanie Berg, Seo-Hyun Kim, Amy Wozniak, Oluwatobi Odetola, Saad Arain
American Journal of Hematology. 2022-06-01
Abstracts/Posters
- Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AMLMelissa L. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Timed sequential therapy with high-dose cytarabine and mitoxantrone as an effective and safe induction regimen for acute myeloid leukemia.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Study Shows Structural Racism Can Result in Poorer Leukemia OutcomesMarch 7th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
